Intelligent Bio Solutions Inc. (INBS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

Market Cap

$6.69M

MomentumView details →

1D Return

−3.91%

YTD Return

−77.12%

RSI (14)

44.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

Market Cap

$6.69M

RSI (14)

44.8

MomentumView details →

1D Return

−3.91%

YTD Return

−77.12%

SummaryUpdated Jun 1, 2026

Intelligent Bio Solutions Inc. (NASDAQ:INBS) is a life sciences company founded in 2016 and headquartered in New York, New York. Originally incorporated as GBS Inc., the company changed its name to Intelligent Bio Solutions Inc. in October 2022. The company went public in December 2020 and operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. INBS focuses on developing non-invasive, real-time monitoring and diagnostic tests that can be used by patients and their primary healthcare practitioners, representing a shift away from traditional invasive blood-based testing methods.

Ask drillr about Intelligent Bio Solutions Inc. →

ProfitabilityView details →

Gross Margin

27.71%

Net Margin

−294.91%

EBITDA Margin

−273.62%

ROE (TTM)

−225.57%

ROA (TTM)

−104.10%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

+38.09%

EPS YoY

+54.52%

FCF YoY

−23.16%

Revenue CAGR 3Y

+49.68%

EPS CAGR 3Y

+57.80%

EBITDA YoY

−23.60%

EarningsView details →

EPS (Actual)

−$1.34

EPS Surprise

15.19%

Beats (12Q)

4/12

Next Q EPS Est

−$1.31

Avg Surprise (4Q)

−287.93%

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

1.44x

Quick Ratio

1.35x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

4.22M

Net Income (TTM)

−12.43M

Op. CF (TTM)

−12.08M

Next earningsNov 11, 2026 →

Latest newsMore news →

Intelligent Bio Solutions Inc. signed a securities purchase agreement on August 31, 2026, to sell 2,036,659 shares of common stock (or pre-funded warrants) with accompanying Series N-1 and N-2 warrants at a combined price of $2.455 per share, raising gross proceeds of approximately $5.0 million in a private placement to a single institutional investor.2d ago

Intelligent Bio Solutions reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by reader installed base and high-margin cartridge growth.16d ago

Similar companies

Trinity Biotech plcTRIB ENDRA Life Sciences Inc.NDRA bioAffinity Technologies, Inc.BIAF BioNexus Gene Lab Corp.BGLC Mainz Biomed B.V.MYNZ iSpecimen Inc.ISPC Find similar companies →

Latest newsMore news →

Intelligent Bio Solutions Inc. signed a securities purchase agreement on August 31, 2026, to sell 2,036,659 shares of common stock (or pre-funded warrants) with accompanying Series N-1 and N-2 warrants at a combined price of $2.455 per share, raising gross proceeds of approximately $5.0 million in a private placement to a single institutional investor.2d ago Intelligent Bio Solutions reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by reader installed base and high-margin cartridge growth.16d ago Intelligent Bio Solutions Inc. announced a significant regulatory milestone for its rapid testing unit, causing its shares to surge on Monday.18d ago